RLMD
Relmada Therapeutics, Inc.
Biotechnology
Market Cap$545M
5Y Perf.-22.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RLMD vs ALTO
Revenue, margins, valuation, and 5-year total return — side by side.
ALTO
Alto Ingredients, Inc.
Chemicals - Specialty
Market Cap$351M
5Y Perf.+580.7%
RLMD vs ALTO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RLMD | ALTO |
|---|---|---|
| Industry | Biotechnology | Chemicals - Specialty |
| Market Cap | $545M | $351M |
| Revenue (TTM) | $0.00 | $918M |
| Net Income (TTM) | $-57M | $13M |
| Gross Margin | — | 3.8% |
| Operating Margin | — | 0.8% |
| Forward P/E | — | 15.4x |
| Total Debt | $0.00 | $98M |
| Cash & Equiv. | $3M | $26M |
RLMD vs ALTO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RLMD
ALTO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Relmada Therapeutic… (RLMD) | 100 | 77.1 | -22.9% |
| Alto Ingredients, I… (ALTO) | 100 | 680.7 | +580.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RLMD vs ALTO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ALTO leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Relmada Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
RLMD
Relmada Therapeutics, Inc.
The Long-Run Compounder
RLMD is the clearest fit if your priority is long-term compounding.
- 312.8% 10Y total return vs ALTO's 6.8%
- 1.5% margin vs ALTO's 1.5%
- +20.6% vs ALTO's +427.8%
Best for: long-term compounding
ALTO
Alto Ingredients, Inc.
The Income Pick
ALTO carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 0.30, yield 0.4%
- Rev growth -4.9%, EPS growth 119.5%, 3Y rev CAGR -11.8%
- Lower volatility, beta 0.30, Low D/E 39.8%, current ratio 2.64x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ALTO | -4.9% revenue growth vs RLMD's -60.5% |
| Quality / Margins | RLMD | 1.5% margin vs ALTO's 1.5% |
| Stability / Safety | ALTO | Beta 0.30 vs RLMD's 1.40 |
| Dividends | ALTO | 0.4% yield; the other pay no meaningful dividend |
| Momentum (1Y) | RLMD | +20.6% vs ALTO's +427.8% |
| Efficiency (ROA) | ALTO | 3.4% ROA vs RLMD's -145.6%, ROIC 1.9% vs -77.3% |
RLMD vs ALTO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
RLMD vs ALTO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLALTOLAGGINGRLMD
RLMDRelmada Therapeutics,…
1leads
ALTOAlto Ingredients, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RLMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALTO1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALTO5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RLMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ALTO leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ALTO and RLMD operate at a comparable scale, with $918M and $0 in trailing revenue.
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $918M |
| EBITDAEarnings before interest/tax | -$59M | $33M |
| Net IncomeAfter-tax profit | -$57M | $13M |
| Free Cash FlowCash after capex | $0 | $9M |
| Gross MarginGross profit ÷ Revenue | — | +3.8% |
| Operating MarginEBIT ÷ Revenue | — | +0.8% |
| Net MarginNet income ÷ Revenue | — | +1.5% |
| FCF MarginFCF ÷ Revenue | — | +0.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +53.2% | +149.1% |
ALTO leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RLMD and ALTO each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| Market CapShares × price | $545M | $351M |
| Enterprise ValueMkt cap + debt − cash | $541M | $423M |
| Trailing P/EPrice ÷ TTM EPS | -5.12x | 28.38x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 15.39x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 12.84x |
| Price / SalesMarket cap ÷ Revenue | — | 0.38x |
| Price / BookPrice ÷ Book value/share | 3.39x | 1.40x |
| Price / FCFMarket cap ÷ FCF | — | 40.58x |
Evenly matched — RLMD and ALTO each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ALTO leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
ALTO delivers a 6.0% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-171 for RLMD. On the Piotroski fundamental quality scale (0–9), ALTO scores 5/9 vs RLMD's 3/9, reflecting solid financial health.
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| ROE (TTM)Return on equity | -170.8% | +6.0% |
| ROA (TTM)Return on assets | -145.6% | +3.4% |
| ROICReturn on invested capital | -77.3% | +1.9% |
| ROCEReturn on capital employed | -96.0% | +2.3% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.40x |
| Net DebtTotal debt minus cash | -$3M | $72M |
| Cash & Equiv.Liquid assets | $3M | $26M |
| Total DebtShort + long-term debt | $0 | $98M |
| Interest CoverageEBIT ÷ Interest expense | — | -0.93x |
ALTO leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RLMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RLMD five years ago would be worth $10,220 today (with dividends reinvested), compared to $7,882 for ALTO. Over the past 12 months, RLMD leads with a +2060.5% total return vs ALTO's +427.8%. The 3-year compound annual growth rate (CAGR) favors RLMD at 103.2% vs ALTO's 49.5% — a key indicator of consistent wealth creation.
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| YTD ReturnYear-to-date | +70.0% | +70.7% |
| 1-Year ReturnPast 12 months | +2060.5% | +427.8% |
| 3-Year ReturnCumulative with dividends | +739.5% | +233.8% |
| 5-Year ReturnCumulative with dividends | +2.2% | -21.2% |
| 10-Year ReturnCumulative with dividends | +312.8% | +6.8% |
| CAGR (3Y)Annualised 3-year return | +103.2% | +49.5% |
RLMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RLMD and ALTO each lead in 1 of 2 comparable metrics.
Risk & Volatility
ALTO is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than RLMD's 1.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RLMD currently trades 92.9% from its 52-week high vs ALTO's 75.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.40x | 0.30x |
| 52-Week HighHighest price in past year | $8.00 | $5.99 |
| 52-Week LowLowest price in past year | $0.32 | $0.80 |
| % of 52W HighCurrent price vs 52-week peak | +92.9% | +75.8% |
| RSI (14)Momentum oscillator 0–100 | 64.0 | 61.1 |
| Avg Volume (50D)Average daily shares traded | 2.0M | 2.1M |
Evenly matched — RLMD and ALTO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RLMD as "Buy" and ALTO as "Buy". Consensus price targets imply 21.1% upside for RLMD (target: $9) vs -22.9% for ALTO (target: $4). ALTO is the only dividend payer here at 0.37% yield — a key consideration for income-focused portfolios.
| Metric | RLMDRelmada Therapeut… | ALTOAlto Ingredients,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $3.50 |
| # AnalystsCovering analysts | 8 | 2 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.02 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ALTO leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RLMD leads in 1 (Total Returns). 2 tied.
Best OverallAlto Ingredients, Inc. (ALTO)Leads 2 of 6 categories
Loading custom metrics...
RLMD vs ALTO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is RLMD or ALTO a better buy right now?
Alto Ingredients, Inc.
(ALTO) offers the better valuation at 28. 4x trailing P/E (15. 4x forward), making it the more compelling value choice. Analysts rate Relmada Therapeutics, Inc. (RLMD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RLMD or ALTO?
Over the past 5 years, Relmada Therapeutics, Inc.
(RLMD) delivered a total return of +2. 2%, compared to -21. 2% for Alto Ingredients, Inc. (ALTO). Over 10 years, the gap is even starker: RLMD returned +312. 8% versus ALTO's +6. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RLMD or ALTO?
By beta (market sensitivity over 5 years), Alto Ingredients, Inc.
(ALTO) is the lower-risk stock at 0. 30β versus Relmada Therapeutics, Inc. 's 1. 40β — meaning RLMD is approximately 362% more volatile than ALTO relative to the S&P 500.
04Which is growing faster — RLMD or ALTO?
On earnings-per-share growth, the picture is similar: Alto Ingredients, Inc.
grew EPS 119. 5% year-over-year, compared to 45. 3% for Relmada Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RLMD or ALTO?
Alto Ingredients, Inc.
(ALTO) is the more profitable company, earning 1. 5% net margin versus 0. 0% for Relmada Therapeutics, Inc. — meaning it keeps 1. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALTO leads at 0. 8% versus 0. 0% for RLMD. At the gross margin level — before operating expenses — ALTO leads at 3. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is RLMD or ALTO more undervalued right now?
Analyst consensus price targets imply the most upside for RLMD: 21.
1% to $9. 00.
07Which pays a better dividend — RLMD or ALTO?
In this comparison, ALTO (0.
4% yield) pays a dividend. RLMD does not pay a meaningful dividend and should not be held primarily for income.
08Is RLMD or ALTO better for a retirement portfolio?
For long-horizon retirement investors, Alto Ingredients, Inc.
(ALTO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). Both have compounded well over 10 years (ALTO: +6. 8%, RLMD: +312. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between RLMD and ALTO?
These companies operate in different sectors (RLMD (Healthcare) and ALTO (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.